Organovo Holdings Inc.

Beleggen in aandelen beurs China Shanghai Composite, Toronto, etc.
Gebruikersavatar
Wallstreet
Forum actieveling
Forum actieveling
Berichten: 430
Lid geworden op: 16 Aug 2012 20:01
waarderingen: 22
Contact:

Re: Organovo Holdings Inc.

Berichtdoor Wallstreet » 29 Nov 2013 18:58

De Wereld schreef:Waarom niet? Beleggers weten immers dat dit een "uniek" bedrijf is.


Als de beleggers wisten dat dit een uniek bedrijf is zou de prijs al hoger staan denk ik.
Ik zou gewoon wachten hoe het volgende keer loopt ^^
Bannerke liked last!
i'm not in this game to make money, i'm in this game to win.



powered by Surfing Waves

Gebruikersavatar
De Wereld
Forum elite
Forum elite
Berichten: 7190
Lid geworden op: 14 Dec 2012 16:08
waarderingen: 1543
Contact:

Re: Organovo Holdings Inc.

Berichtdoor De Wereld » 05 Dec 2013 19:56

Genoeg stof om Wallstreet de mond te snoeren, evenals de zo maar duimpjes gevende "groenen", die zelfs het aandeel niet kent de das om te doen. :lol: :lol:

http://www.finanznachrichten.de/nachric ... gs-inc.htm" onclick="window.open(this.href);return false;

In een negatief sentiment toch nog een aandeel dat het weer schitterend doet. :lol:

Gebruikersavatar
Wallstreet
Forum actieveling
Forum actieveling
Berichten: 430
Lid geworden op: 16 Aug 2012 20:01
waarderingen: 22
Contact:

Re: Organovo Holdings Inc.

Berichtdoor Wallstreet » 05 Dec 2013 20:04

De Wereld schreef:Genoeg stof om Wallstreet de mond te snoeren, evenals de zo maar duimpjes gevende "groenen", die zelfs het aandeel niet kent de das om te doen. :lol: :lol:

http://www.finanznachrichten.de/nachric ... gs-inc.htm" onclick="window.open(this.href);return false;

In een negatief sentiment toch nog een aandeel dat het weer schitterend doet. :lol:


Waarom om mij de mond te snoeren?
ONVO stond enkele weken(!) geleden 13$. Nu zijn ze wel +5% maar ze staan nog 'maar' 9,70$
Mannie liked last!
i'm not in this game to make money, i'm in this game to win.

Gebruikersavatar
Mannie
Premiummember
Premiummember
Berichten: 1363
Lid geworden op: 01 Feb 2012 11:06
Locatie: Paperassen
waarderingen: 359
Contact:

Re: Organovo Holdings Inc.

Berichtdoor Mannie » 05 Dec 2013 20:13


Gebruikersavatar
De Wereld
Forum elite
Forum elite
Berichten: 7190
Lid geworden op: 14 Dec 2012 16:08
waarderingen: 1543
Contact:

Re: Organovo Holdings Inc.

Berichtdoor De Wereld » 05 Dec 2013 20:34


@ Mannie
Je haalt hier wel oude koeien uit de sloot!

@ Wallstreet
Kijk je alleen maar naar de koers om de waarde van het bedrijf te kennen? Hoeveel mensen kennen op de dag van vandaag "Organovo" nog niet? Het is immers de uitdaging voor de toekomst?
Elke bedrijf is laag moeten beginnen, maar dat wil niet zeggen dat ze het naar de toekomst toe zich niet kunnen waar maken. Zo lang ze naar geen kopietje maken van "Wallstreet" zelf is het oké, want dan zou het een al te gekke wereld worden. :lol: :lol:
Heb je dan meer vertrouwen in THR, Ablynx, Tigenix of misschien ... in je zelf!
Je bent gewoonweg een vlieg, die op de as van het wiel zit en zegt "Zie, wat een stof laat ik opwaaien! Ik ken er alles van! Ik weet het steeds beter dan de anderen!"

Maar goed, mij maakt het niet uit: ondertussen kan ik weer iets meer dan 3.700 € bijschrijven in mijn kasboek en dat alleen maar voor Organovo. :P

Gebruikersavatar
Wallstreet
Forum actieveling
Forum actieveling
Berichten: 430
Lid geworden op: 16 Aug 2012 20:01
waarderingen: 22
Contact:

Re: Organovo Holdings Inc.

Berichtdoor Wallstreet » 05 Dec 2013 20:40

De Wereld schreef:

@ Mannie
Je haalt hier wel oude koeien uit de sloot!

@ Wallstreet
Kijk je alleen maar naar de koers om de waarde van het bedrijf te kennen? Hoeveel mensen kennen op de dag van vandaag "Organovo" nog niet? Het is immers de uitdaging voor de toekomst?
Elke bedrijf is laag moeten beginnen, maar dat wil niet zeggen dat ze het naar de toekomst toe zich niet kunnen waar maken. Zo lang ze naar geen kopietje maken van "Wallstreet" zelf is het oké, want dan zou het een al te gekke wereld worden. :lol: :lol:
Heb je dan meer vertrouwen in THR, Ablynx, Tigenix of misschien ... in je zelf!
Je bent gewoonweg een vlieg, die op de as van het wiel zit en zegt "Zie, wat een stof laat ik opwaaien! Ik ken er alles van! Ik weet het steeds beter dan de anderen!"

Maar goed, mij maakt het niet uit: ondertussen kan ik weer iets meer dan 3.700 € bijschrijven in mijn kasboek en dat alleen maar voor Organovo. :P



1) ik volg geen belgische/nederlandse aandelen.
2) Ik ben geen vlieg zoals je zegt. Als een aandeel op een dag 25% crasht is dit niet normaal & als ze minstens 10 jaar staan van een clinical trial is dit ook niet normaal.// volgens mij draait u de rollen om en bent u die vlieg. U pakt alleszins vaak , ongevraagd, uit met uw 'winsten' ---persoonlijke mening---

Maar goed, dit jaar is mijn portfolio met 200% + gestegen. =)
i'm not in this game to make money, i'm in this game to win.

kravat
Forum actieveling
Forum actieveling
Berichten: 302
Lid geworden op: 05 Apr 2013 08:46
waarderingen: 45
Contact:

Re: Organovo Holdings Inc.

Berichtdoor kravat » 11 Dec 2013 11:07

Minder leuk :
http://seekingalpha.com/article/1890861 ... e_readmore" onclick="window.open(this.href);return false;

Gebruikersavatar
De Wereld
Forum elite
Forum elite
Berichten: 7190
Lid geworden op: 14 Dec 2012 16:08
waarderingen: 1543
Contact:

Re: Organovo Holdings Inc.

Berichtdoor De Wereld » 15 Dec 2013 18:24

De toen gedode vogel schreef:• Shares of Organovo (ONVO) are lower by 8.5% in premarket trading.
• The company announced an equity distribution agreement on Wednesday under which it may offer as many as 4M shares from time to time. (8-K)

Vorige kapitaalsverhoging was ideaal moment voor velen om aan te kopen / bij te tanken.


Ik heb ONVO voor een derde maal bijgekocht. Totaal aantal shares: 3000. Nu stop ik echter met inkopen. Ik ben tuk op dit aandeel. :D

Gebruikersavatar
De Wereld
Forum elite
Forum elite
Berichten: 7190
Lid geworden op: 14 Dec 2012 16:08
waarderingen: 1543
Contact:

Re: Organovo Holdings Inc.

Berichtdoor De Wereld » 14 Jan 2014 20:24

Organovo Announces Collaboration with National Institutes of Health


By PR Newswire, January 14, 2014, 08:05:00 AM EDT

SAN DIEGO and BETHESDA, Md., Jan. 14, 2014 /PRNewswire/ -- Organovo announced today that they are joining together with two institutes from the National Institutes of Health (NIH) to help scientists develop more reliable tools for bringing safer, more effective treatments to patients on a faster timeline. Organovo is collaborating with the National Center for Advancing Translational Sciences (NCATS) and the National Eye Institute (NEI) to develop better and more clinically predictive tissue models using Organovo's NovoGen MMX Bioprinter®. Organovo will collaborate with NCATS and NEI in using the NovoGen Bioprinting platform to create three-dimensional, architecturally correct, functional living tissues.

"Researchers who develop new therapies for patients are too often hampered by animal models and traditional cell culture models that are poor predictors of drug efficacy and toxicity in human beings," says Keith Murphy, Organovo's Chief Executive Officer. "Our 3D printer creates living human tissues that more closely reproduce in vivo human tissues. In collaboration with NIH, which has worked to highlight and address the critical need for better models that can lead to better drugs, we hope to create tissue models that give researchers a much more accurate view of how drugs will behave in human beings before those drugs ever enter clinical trials."

"Developing collaborations like this are central to NCATS' mission," said NCATS Director Christopher P. Austin, M.D. "We look forward to working with Organovo and our colleagues at NEI to develop a printable eye tissue. We also plan to develop additional tissue models that complement and leverage our current Tissue Chip and compound screening programs."

"This technology could provide us with a renewable and easy-to-manipulate source of functional eye tissue," said NEI Director Paul A. Sieving, M.D., Ph.D. "Printable eye tissue could be used to identify disease pathways and to screen for and discover new therapeutic drugs."

For more information about NCATS and NEI, visit http://www.ncats.nih.gov" onclick="window.open(this.href);return false; and http://www.nei.nih.gov" onclick="window.open(this.href);return false;.

About Organovo Holdings, Inc.

Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The Company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. In addition to numerous scientific publications, the Company's technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and numerous others. Organovo is changing the shape of medical research and practice. Learn more at http://www.organovo.com" onclick="window.open(this.href);return false;.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the market acceptance for the Company's products, and the risks related to the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our report on Form 10-Q filed November 8, 2013, the prospectus supplement filed with the SEC on August 2, 2013 and the transition report on Form 10-KT filed with the SEC on May 24, 2013 and our other filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.

SOURCE Organovo Holdings, Inc.


Read more: http://www.nasdaq.com/press-release/org ... z2qP0fjmCD" onclick="window.open(this.href);return false;

Gebruikersavatar
De Wereld
Forum elite
Forum elite
Berichten: 7190
Lid geworden op: 14 Dec 2012 16:08
waarderingen: 1543
Contact:

Re: Organovo Holdings Inc.

Berichtdoor De Wereld » 29 Jan 2014 16:07

SAN DIEGO, Jan. 29, 2014/PRNewswire/ -- Organovo Holdings, Inc. (NYSE MKT:ONVO) ("Organovo"), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, today announced that it has performed its first 3D Liver tissue delivery.

The achievement marks the delivery of Organovo's 3D Liver tissue to a laboratory outside of the company to a key opinion leader (KOL) for experimentation, and marks the achievement of a milestone along the pathway to commercial launch of its 3D liver tissue product. Organovo achieved the milestone ahead of its April 2014 target date. Key opinion leaders are generally experts, in this case top research scientists, in a particular field whose opinions and publications will influence practice. Organovo expects KOLs to make recommendations on improvements to the tissue before launch and to influence peers through their reporting of their research results at conferences and through peer reviewed publications.

"This is an important milestone for Organovo R&D," said Organovo Chief Technology Officer and Executive Vice President of Research and Development Dr. Sharon Presnell. "In developing these tissues, we have gone through a careful set of research studies involving many individual tissues, and greatly increased our ability to produce them. By the end of January, we expect to have bioprinted nearly four hundred 3D Liver tissues during the month."

Organovo also introduced updated guidance on the timing of its product launch. Organovo had planned to launch its 3D Liver tissue product by the end of December 2014. It now expects to commence the commercial launch and start generating revenue through a services model prior to December 2014. "As pharmaceutical and biotechnology companies move to continue to outsource their R&D efforts," explained Keith Murphy, Organovo's chief executive officer, "our ability to deliver a service offering in addition to products will be critical to meet their needs and to enter the $7B preclinical research services market." The company anticipates that preclinical toxicology testing services can command prices in the high tens of thousands of dollars per compound for standard screening for liver alone.

Organovo's 3D Liver tissues exhibit several key features that remain stable over time:
• Tissue-like cellular density;
• Multi-layered architecture with multiple cell types positioned relative to one another, reaching up to 500 microns thickness, with tissues comprised of up to 20 cell layers;
• Albumin production 5-9 times greater than matched 2D controls, suggesting superior functionality;
• Stable albumin production for over 40 days, fibrinogen and transferrin production, and inducible cytochrome P450 enzymatic activities, including CYP 1A2 and CYP 3A4;
• Cholesterol biosynthesis, which has been demonstrated for the first time in a multi-cellular 3D human liver system in vitro;
• Evidence of the formation of tight junctions in the liver tissues, demonstrated by cadherin and claudin staining by day 3 of tissue formation; and
• Demonstration of appropriate response to hepatotoxic insults from acetaminophen, acetaminophen in combination with ethanol, and diclofenac.

Organovo plans to release additional data in 2014 on its 3D Kidney tissues and breast cancer tissues now in development. In December, Organovo demonstrated that its NovoGen bioprinted breast cancer tissues retain compartmentalized structures with interaction between stromal and cancer cells, along with formation of endothelial networks and differentiation of adipocytes. NovoGen 3D bioprinted constructs were demonstrated to be less susceptible to tamoxifen-induced toxicity than isolated 2D cancer cells when treated with the same dose of tamoxifen for the same duration, highlighting the potential utility of this model in identifying superior drugs with greater toxicity against complex, multicellular 3D tumor models.

Organovo also reminded investors of the continued availability of Organovo'sDecember 5, 2013 online presentation. Organovo's Chairman and Chief Executive Officer, Keith Murphy, presented in a live interactive online forum that was a recorded event. The online content that can be accessed consists of a 30 min presentation as well as the text of a Q&A session that followed.

LINK: http://www.retailinvestorconferences.com" onclick="window.open(this.href);return false; > click on red "register / watch event now" button

The Company also reminded investors of its guidance to investors regarding "Short and Distort" articles.

About Organovo Holdings, Inc.

Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The Company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. In addition to numerous scientific publications, the Company's technology has been featured in The Wall Street Journal, Time Magazine, and The Economist. Organovo is changing the shape of medical research and practice. Learn more at http://www.organovo.com" onclick="window.open(this.href);return false; .

Safe Harbor State

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the timing of commercial launch and the market acceptance and potential for the Company's products, and the risks related to the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including the prospectus supplement that we filed with the SEC on November 27, 2013 and the transition report on Form 10-KT for the period ended March 31, 2013 that we filed with the SEC on May 24, 2013 and our other filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.

SOURCE Organovo Holdings, Inc.


Read more: http://www.nasdaq.com/press-release/org ... z2rng8efw0" onclick="window.open(this.href);return false;


Tijdelijke promo tot 31 augustus:






Reageren en meer functies krijgen?

Discussieer met duizenden beleggers, minder advertenties, ideaal voor smartphone, betere gebruikservaring en gratis abonneren op favoriete onderwerpen.

Registreer binnen enkele tellen